- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05097053
A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19
A Parallel Group, Prospective, Randomized, Two-arm, Open-label Study to Evaluate the Immunogenicity, Safety, and Tolerability of Heterologous 3rd Boost of MVC-COV1901 in Adults With 2 Doses of ChAdOx1-nCov-19 in 3 Months and 6 Months
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This a parallel group, prospective, randomized, two-arm, open-label, single-center study to be conducted in approximately 200 healthy participants aged 20 to 64 years who have had their two doses of ChAdOx1-nCov-19 (Astra Zeneca). Preparation and administration of study intervention will be performed by authorized unblinded site personnel. Eligible participants will receive MVC-COV1901 vaccine after a 3-month (Group A: < 16 weeks and ≥ 12 weeks) or 6-month (Group B: < 28 weeks and ≥ 24 weeks) interval apart from their second dose of ChAdOx1-nCov-19.
The study consists of 6 on-site visits:
- Day -28 to Day 1, Visit 1 (Screening)
- Day 1, Visit 2 (study intervention) : randomization Group A and B
Group A:
- Day 1, Visit 2: treatment
- Day 29 ± 3 days, Visit 3
- Day 85 ± 3 days, Visit 4
- Day 169 ± 3 days, Visit 5
Group B:
- Day 1, Visit 2
- Day 85 ± 3 days, Visit 3: treatment
- Day 113 ± 3 days, Visit 4
- Day 169 ± 3 days, Visit 5
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Chieh-Yu Cheng, MD.PhD.
- Telefonnummer: 8311 +886-3-3699721
- E-post: s841060@gm.ym.edu.tw
Studera Kontakt Backup
- Namn: Shu-Hsing Cheng, MD.PhD.
- Telefonnummer: 8311 +886-3-3699721
- E-post: shcheng@mail.tygh.gov.tw
Studieorter
-
-
-
Taoyuan, Taiwan
- Rekrytering
- Taoyuan General Hospital
-
Kontakt:
- Chieh-Yu Cheng, M.D., Ph.D.
- Telefonnummer: 8311 +886-3-3699721
- E-post: s841060@gm.ym.edu.tw
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female participant aged 20 to 64 years at randomization.
- Has received two doses of the ChAdOx1-nCov-19 (Astra-Zeneca) 12 to 16 weeks before randomization.
Female participant must:
- Be either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal;
- Or, if of childbearing potential, be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. Acceptable forms include:
i.Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system ii.Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository c.Have a negative pregnancy test
- Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
- Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.
Exclusion Criteria:
- Pregnant or breast feeding or have plan to become pregnant within 30 days after the last administration of study intervention.
- Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.
- Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.
- Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.
- Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.
- Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.
- Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention.
- Has received any other investigational or licensed COVID-19 vaccine.
- Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
- A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
- Bleeding disorder considered a contraindication to IM injection or phlebotomy.
- Known SARS-CoV-2 infection in the recent 3 months prior to the first dose of study intervention.
- A history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome.
- Participant who, in the investigator's judgement, is not in a stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include a participant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.
- A history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.
- Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: MVC-COV1901 vaccine (3-month Interval)
There will be approximately 100 participants (Group A) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 1
|
MVC-COV1901 vaccine after a 3-month Interval
|
Experimentell: MVC-COV1901 vaccine (6-month Interval)
There will be approximately 100 participants (Group B) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 85.
|
MVC-COV1901 vaccine after a 6-month Interval
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Primary Immunogenicity
Tidsram: Day1 to 28 days after vaccination
|
To evaluate the immunogenicity of heterologous third-boost (MVC-COV1901) in 3 months, compared to 6 months, in terms of neutralizing antibody Geometric Mean Titers (GMT) |
Day1 to 28 days after vaccination
|
Primary Safety
Tidsram: Day1 to 28 days after vaccination
|
To evaluate the safety and tolerability of heterologous third-boost (MVC-COV1901) from Day 1 to 28 days after the study intervention The number and percentage of participants with the occurrence of:
|
Day1 to 28 days after vaccination
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Secondary Immunogenicity
Tidsram: Day 1 and Day 169
|
To evaluate the immunogenicity of heterologous third-boost (MVC-COV1901) in terms of antigen-specific immunoglobulin titers GMT |
Day 1 and Day 169
|
Secondary Safety
Tidsram: Day 1 to Day169
|
To evaluate the safety of heterologous third-boost (MVC-COV1901), over the study period The number and percentage of participants with the occurrence of:
|
Day 1 to Day169
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Exploratory Efficacy
Tidsram: Day 1 to Day 169
|
To estimate the efficacy of heterologous third-boost (MVC COV1901), in the prevention of COVID-19
|
Day 1 to Day 169
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Chieh-Yu Cheng, MD.PhD., Taoyuan General Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TYGH110044
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Covid-19 vaccin
-
Stanford UniversityViamoAvslutadKunskap om COVID-19-vaccin | Covid-19 vaccin troFörenta staterna
-
EyeGene Inc.Novotech (Australia) Pty LimitedAktiv, inte rekryterande
-
University of WashingtonCenters for Disease Control and PreventionRekryteringCovid-19 | Vaccin tveksamhetFörenta staterna
-
Masaryk UniversityRekryteringBiverkningar på vaccin | Covid-19 vaccinPolen, Kanada, Förenta staterna, Kroatien, Tjeckien, Estland, Etiopien, Tyskland, Ghana, Mexiko, Portugal, Ryska Federationen, Serbien, Slovenien
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Duke University och andra samarbetspartnersAvslutadVaccin tveksamhet | Covid-19 vaccinFörenta staterna
-
Korea University Guro HospitalAjou University School of Medicine; Korean Center for Disease Control and... och andra samarbetspartnersRekryteringInflammation | Vaccin biverkning | Vaccin immunsvar | Covid-19-vaccinationKorea, Republiken av
-
Chulalongkorn UniversityNational Vaccine Institute, Thailand; Chula Vaccine Research Center (ChulaVRC)... och andra samarbetspartnersAvslutad
-
Cancer Institute and Hospital, Chinese Academy...RekryteringCovid-19 vaccin | Covid-19 infektionKina
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical... och andra samarbetspartnersAvslutadLunginflammation, Viral | Covid-19 vaccin | COVID-19 sjukdom | SARS lunginflammationVietnam
-
Mahidol UniversityClinixir Co., Ltd.; Program Management Unit-C (PMU-C), governed by Ministry...AvslutadCovid-19 infektion | COVID-19 VACCINThailand
Kliniska prövningar på MVC-COV1901(3 Months)
-
Medigen Vaccine Biologics Corp.Avslutad
-
Medigen Vaccine Biologics Corp.Avslutad
-
Medigen Vaccine Biologics Corp.Avslutad
-
Medigen Vaccine Biologics Corp.Coalition for Epidemic Preparedness InnovationsAvslutad
-
Rhizen Pharmaceuticals SAIncozen Therapeutics Pvt LtdRekryteringTrippel negativ bröstcancer (TNBC)Indien
-
Medigen Vaccine Biologics Corp.Avslutad
-
Medigen Vaccine Biologics Corp.AvslutadCovid-19 vaccinParaguay
-
Medigen Vaccine Biologics Corp.Avslutad
-
Chang Gung Memorial HospitalMedigen Vaccine Biologics Corp.Aktiv, inte rekryterandeCovid-19 | GenombrottsinfektionTaiwan
-
Medigen Vaccine Biologics Corp.Avslutad